# US 11,111,302 B2 · Anti HLA-G specific antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,302 B2
- Document ID: US11111302B2
- Status: Granted
- Kind: B2
- Application number: 17/080,017
- Filed: 2020-10-26
- Published: 2021-02-25
- Granted: 2021-09-07
- Earliest claimed: 2016-06-03
- Assignees: Invectys
- Applicants: Invectys SA
- Inventors: Pierre Langlade Demoyen; Thierry Huet; Julien Caumartin; Maria Loustau; Maria Wehbe
- Web page: https://patentgrep.com/patent/US11111302B2

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/50: Cyclic peptides containing at least one abnormal peptide link
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the α3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

## Claims

### Claim 1

An anti-human leukocyte antigen G (HLA-G) antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises:
(a) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO: 8, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO: 10, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO: 12; and
(b) a light chain variable region (VL), which comprises a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO: 2, a light chain complementarity determining region 2 (LC CDR2) of sequence KVS and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO: 5.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the VH comprises SEQ ID NO: 64 and the VL comprises SEQ ID NO: 63.

### Claim 3 (depends on 2)

The antibody or antigen-binding fragment of claim 2, wherein the antibody is a full-length immunoglobulin G comprising two heavy chains and two light chains.

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment is humanized or chimeric.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the VH, the VL, or both the VH and VL comprise human immunoglobulin framework region sequences.

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody comprises an immunoglobulin constant region.

### Claim 7 (depends on 1)

The antigen-binding fragment of claim 1, wherein the antigen-binding fragment is a Fv, a dsFv, a scFv, a Fab, a Fab′, or a F(ab′)2.

### Claim 8 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody is monoclonal.

### Claim 9 (depends on 1)

A conjugate comprising the antibody or antigen-binding fragment of claim 1 linked to a cytotoxic agent.